Key result
Olezarsen reduces triglycerides by ~59% versus usual care in patients with hypertriglyceridemia.
Why the study?
Hypertriglyceridemia increases cardiovascular risk, and this meta-analysis was performed to evaluate the safety and efficacy of the novel antisense therapy olezarsen to guide clinical decision-making.
Does olezarsen reduce triglyceride levels and improve atherogenic lipid parameters in patients with hypertriglyceridemia?
Meta-Analysis
Does olezarsen reduce triglyceride levels and improve atherogenic lipid parameters in patients with hypertriglyceridemia?
Mean Difference: -58.57 (95% CI -63.1–-54.04)
Olezarsen effectively reduces triglycerides and apolipoprotein C-III in patients with hypertriglyceridemia, supporting its potential as a novel lipid-lowering therapy despite some injection-site and liver enzyme issues.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“These results add to the collective body of evidence for olezarsen, showing the reduction of acute pancreatitis risk in severe hypertriglyceridemia. As rates of acute pancreatitis continue to increase, olezarsen has the potential to be an important part of a preventative approach to disease management in at-risk patients.”
“According to EAS/ESC guidelines, triglyceride levels above 10 mmol/L warrant urgent intervention to prevent acute pancreatitis. This new analysis showed that olezarsen reduced acute pancreatitis risk by 85% in patients with baseline triglyceride levels ≥10 mmol/L, while the vast majority of patients achieved triglyceride levels below 10 mmol/L.”
“People living with sHTG are at risk of acute pancreatitis, a debilitatingly painful complication that can potentially be life-threatening and cause other serious health consequences. Standard lipid-lowering therapies only offer modest benefits, underscoring the urgent need for innovative new treatment options.”
Supports olezarsen to lower pancreatitis risk in severe hypertriglyceridemia; extends RCT evidence on efficacy and safety.
Hypertriglyceridemia is a frequently seen lipid disorder. It is linked to a higher risk of cardiovascular diseases and adds a significant burden on healthcare systems. Olezarsen, a novel antisense therapy targeting apolipoprotein C-III, offers effective triglyceride reduction with the convenience of infrequent dosing. This meta-analysis evaluates the safety and efficacy of olezarsen in hypertriglyceridemia to guide clinical decision-making. A comprehensive literature search across major databases identified randomized control trials comparing olezarsen with usual care in patients with hypertriglyceridemia. Data extraction and bias assessment were conducted independently, using RoB 2.0 and the GRADE framework. A meta-analysis was performed using RevMan 5.4.1, applying random effects models and assessing heterogeneity with the I2 statistic. Eight randomized controlled trials were included. Olezarsen significantly reduced triglycerides (MD -58.57, 95% CI -63.10 to -54.04; I2 = 13%) and apolipoprotein C-III (MD -69.81, 95% CI -75.77 to -63.84; I2 = 56%). Significant improvements were also observed in apolipoprotein B, nonhigh-density lipoprotein cholesterol, and achievement of TAG targets (<150 mg/dL). There was no increase in overall or serious adverse events, although injection-site reactions, liver enzyme elevations, and treatment discontinuation were higher with olezarsen. Olezarsen significantly improves TAG levels and atherogenic lipid parameters in patients with hypertriglyceridemia, demonstrating robust efficacy across multiple outcomes. It maintains an overall favorable safety profile, supporting its role as a promising therapeutic option, although monitoring for liver enzymes and injection-site reactions is warranted.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) conducted a meta-analysis in Hypertriglyceridemia. Olezarsen vs. usual care was evaluated on triglycerides (MD -58.57, 95% CI -63.10 to -54.04). Olezarsen significantly reduced triglycerides (MD -58.57; 95% CI -63.10 to -54.04) compared to usual care in patients with hypertriglyceridemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: